District Court Grants Government’s Motion to Dismiss Legal Challenge to Medicare Rate Cut for 340B Discounted Drugs

by King & Spalding

On December 29, 2017, the United States District Court for the District of Columbia granted the government’s motion to dismiss a pre-implementation challenge to CMS’s policy to cut the Medicare reimbursement rate for separately payable outpatient drugs by nearly 30 percent. The legal challenge was brought by the American Hospital Association, the Association of American Medical Colleges, America’s Essential Hospitals as well as three public and not-for-profit hospitals. The District Court found that it lacked subject matter jurisdiction to hear the plaintiffs’ challenge because plaintiffs had failed to present their claims through the administrative review process as required by 42 U.S.C. § 405(g).

Background: The 340B Drug Pricing Program

Since 1992, the 340B Program allows eligible hospitals and certain other healthcare providers, otherwise referred to as “covered entities,” to purchase covered outpatient drugs at discounted rates from pharmaceutical manufacturers. The discount formula is set forth in statute, but generally equates to a large reduction in the average manufacturer price. Although only covered outpatient drugs are eligible for discount purchasing, 340B drugs can be provided to any outpatient regardless of whether the patient is covered by insurance. This feature of the Program means that, in some cases, insurers may reimburse covered entities at rates that exceed the 340B discounted pricing. Until 2018, for example, the Medicare program reimbursed hospitals for separately payable outpatient drugs at a rate equal to the average sales price (ASP) of the drug plus a fixed percentage (for example, ASP + 6 percent). Covered entities, which include disproportionate share hospitals, are expected to use these savings to expand services to low-income individuals and other vulnerable populations.

The 2018 Outpatient Prospective Payment Rule

On July 13, 2017, CMS issued the Outpatient Prospective Payments System (OPPS) proposed rule which included a proposal to reduce the reimbursement rate for separately payable outpatient drugs purchased through the 340B Program to ASP minus 22.5 percent, which would cut the payment rate for these drugs by nearly 30 percent. CMS based its decision, in part, on a recent MedPAC study which concluded that 340B hospitals received an average discount of 22.5 percent of the average sales price of drugs. The low acquisition cost combined with high Medicare reimbursement rate might encourage unnecessary utilization of certain 340B drugs, according to CMS. CMS proposed to cut the OPPS reimbursement rate for separately payable drugs to ASP minus 22.5 percent which, CMS estimated, would reduce Medicare payments for these drugs by approximately $900 million. Plaintiffs submitted public comments to the proposed rule, arguing among other things that CMS was required to set the reimbursement rate for separately payable outpatient drugs to either the average hospital acquisition costs, as determined by a survey of hospital acquisition data, or the average sales price of the drug. CMS did not, according to these comments, have the authority to adjust the ASP methodology so drastically without actual hospital survey data. Plaintiffs also noted that the 30-percent reduction in reimbursement would significantly hinder hospitals’ abilities to provide necessary services to vulnerable patients. Despite this opposition, CMS asserted it had broad discretion to adjust 340B Program payment rates and finalized the originally proposed payment scheme on November 13, 2017.

The Suit Against CMS

Soon after CMS published its final rule, plaintiffs sued CMS, challenging the agency’s decision to set the Medicare payment rate for separately payable outpatient drugs at ASP minus 22.5 percent. Plaintiffs also moved for a preliminary injunction to enjoin CMS from implementing the nearly 30-percent rate cut on January 1, 2018, arguing that the hospitals would be irreparably harmed by these reimbursement changes. The government opposed the request for a preliminary injunction and also moved to dismiss, claiming that the District Court did not have subject matter jurisdiction to hear the plaintiffs’ claims. The District Court heard oral argument from both parties on December 21, 2017, and issued its decision on December 29, 2017.

Court Grants Government’s Motion to Dismiss the Motion for Preliminary Injunction as Moot

The Social Security Act prohibits Federal courts from exercising jurisdiction over a claim arising under the Medicare statute unless the Secretary of the Department of Health and Human Services has issued a final decision on the claim following a hearing. 42 U.S.C. § 405(g). Courts have generally interpreted this statutory provision as requiring parties who wish to challenge a final decision of the Secretary to first present their claims to the agency and channel their challenge through an administrative review or appeal process. See Shalala v. Ill. Council on Long Term Care, Inc., 529 U.S. 1 (2000). Only once they have exhausted these administrative remedies and received a final decision of the Secretary can plaintiffs bring their claims to Federal courts.

The District Court concluded that it lacked subject matter jurisdiction under 42 U.S.C. § 405(g) because the plaintiffs had not sought administrative resolution of their claims before proceeding to Federal court. The District Court acknowledged that, in some circumstances, the requirement to exhaust administrative remedies can be waived, but the Court held that the requirement to first present one’s claims to the Secretary cannot. Because plaintiffs had not presented their claims to the Secretary prior to filing suit, the Court concluded it was without jurisdiction.

In reaching this decision, the Court rejected the plaintiffs’ argument that they presented their claims to the Secretary in the comments they filed in responded to the proposed OPPS rule. The District Court concluded that the comments submitted during rulemaking were not sufficiently particularized, and the plaintiffs could only present a challenge to the Secretary’s rate reduction by submitting a claim for reimbursement seeking a higher payment for a covered outpatient drug. Plaintiffs did not, and could not, do this, of course, because the lower reimbursement rates had not yet gone into effect.

Notably, the District Court did not rule on either the merits of the plaintiffs’ claims against the CMS outpatient drug rate cut or the plaintiffs’ request for a preliminary injunction. Thus, the plaintiffs in this lawsuit or any other hospital that is affected by the rate cut could presumably move forward with another legal challenge after presenting their claims to the Secretary. There is no word yet as to whether the plaintiffs in this case will appeal the District Court’s ruling.

The Memorandum Opinion is available here.

Written by:

King & Spalding

King & Spalding on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.